SCHEMBL4825757

SCHEMBL4825757

NC1=c2ccsc2=NCN1c1ccc(NC(=O)Cc2cc(F)ccc2F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 2/20 0.48
▸ LCK P06239 1/20 0.47
▸ AURKB Q96GD4 1/20 0.47
▸ EIF2AK3 Q9NZJ5 1/20 0.47
▸ CSF1R P07333 1/20 0.38
▸ ANO1 Q5XXA6 3/20 0.38
▸ POLB P06746 2/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36
▸ NTRK1 P04629 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HDAC3 O15379 2/20 0.35
▸ HDAC1 Q13547 2/20 0.35
▸ HDAC2 Q92769 2/20 0.35
▸ NCOR2 Q9Y618 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833596 0.84 MAPK8 (0.45) MAPK8CSF1RPOLBMAPTLMNA
SCHEMBL4833937 0.84 NPC1 (0.43) POLBMAPTLMNANPC1RAB9A
SCHEMBL4835896 0.82 ELOVL1 (0.42) ALOX15MAPTNPC1RAB9AHDAC3
SCHEMBL4836546 0.81 KDM4E (0.52) MAPK8CSF1RMAPTHTTNPC1
SCHEMBL4836046 0.80 PSEN1 (0.44) MAPK8NTRK1MAPTLMNAHTT
SCHEMBL4826956 0.77 JAK2 (0.43) MAPTLMNAHTTNPC1RAB9A
SCHEMBL4825635 0.76 NTRK1 (0.40) MAPK8CSF1RPOLBNTRK1MAPT
SCHEMBL4835290 0.73 RAB9A (0.49) POLBMAPTLMNAHTTNPC1
SCHEMBL4826352 0.71 IDO1 (0.38) LMNANPC1RAB9AHDAC3HDAC1
SCHEMBL4825766 0.70 MAPK8 (0.47) MAPK8LCKAURKBEIF2AK3CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MAPK8 1029/4885LCK 94/4885AURKB 160/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MAPK8 2025/4885LCK 94/4885AURKB 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback